Spots Global Cancer Trial Database for Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer
Official Title: Prognostic Evaluation of Changing Endocrine Therapy in Perimenopausal and Recently Postmenopausal Women With Early-stage Hormone Receptor-Positive Breast Cancer
Study ID: NCT02097459
Conditions
Study Description
Brief Summary: It suggests in the Guideline that the postmenopausal women with breast cancer who have taken selective estrogen receptor modulators (SERMs) therapy for 2-3 years could benefit from changing endocrine therapy to aromatase inhibitors (AIs). This is a prospective, randomized and non-inferior trial to evaluate the prognosis of changing endocrine therapy from SERMs to AIs in perimenopausal and recently postmenopausal women with early-stage hormone receptor-positive breast cancer.
Detailed Description:
Eligibility
Minimum Age: 45 Years
Eligible Ages: ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Peking Union Medical College Hospital, Beijing, , China
Contact Details
Name: Qiang Sun, Doctor
Affiliation: Peking Union Medical College Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
